MedTrace Logo

HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC

NCT07045558 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2025-07-01

No results posted yet for this study

Summary

Patients with unresectable HCC will be enrolled in the cohort and will receive the combination therapy of HAIC and atezolizumab plus bevacizumab. The objective response rate is the primary endpoint, and the secondary endpoint includes disease control rate, conversion rate, pathologic complete response, major pathologic response, progression-free survival, recurrence-free survival, overall survival, quality of life, and safety.

Conditions

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-01
Primary Completion
2026-07-31
Completion
2028-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07045558 on ClinicalTrials.gov